NCT00819767

Efficacy and Safety of Aliskiren in Patients With Mild to Moderate Hypertension During Exercise

An Eight-week, Randomized, Double-blind, Parallel-group, Pilot Study to Evaluate the Efficacy and Safety of Aliskiren 300 mg in Comparison With Valsartan 320 mg in Patients With Mild to Moderate Hypertension During Exercise After a Missed Dose

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 68 (actual)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

This study compared the blunting effect of aliskiren and valsartan monotherapies on exercise-induced rises in systolic blood pressure in patients with mild to moderate essential hypertension.

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	Aliskiren	Aliskiren was supplied in 150 mg tablets.
DRUG	Valsartan	Valsartan was supplied in 160 mg capsules.
DRUG	Placebo to aliskiren	Placebo to aliskiren was supplied in tablets matching aliskiren 150 mg.
DRUG	Placebo to valsartan	Placebo to valsartan was supplied in capsules matching valsartan 160 mg.

Timeline

• Start date: 2009-02-01
• Primary completion: 2009-10-01
• Completion: 2009-10-01
• First posted: 2009-01-09
• Last updated: 2011-06-28
• Results posted: 2011-06-28

Locations

8 sites across 4 countries: Czechia, Hungary, Singapore, United Kingdom